MedTrace Logo

Multiple Dose Escalation Study In Medically Stable Subjects With Psoriasis

NCT01736696 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 59

Last updated 2013-02-20

Study results available
· View outcomes & findings →

Summary

This study was conducted in subjects with psoriasis to evaluate drug activity in this patient population by analysis of changes in psoriatic lesion biopsy characteristics. This subject population was selected to evaluate potentially relevant biological activity of CP-690,550 as well as assessing safety and pharmacokinetics.

Conditions

Interventions

DRUG

tofacitinib

5 mg BID For 13 days and once on Day 14

DRUG

tofacitinib

10 mg BID for 13 days and once on Day 14\*

DRUG

tofacitinib

20 mg BID for 13 days and once on Day 14

DRUG

tofacitinib

30 mg BID for 13 days and once on Day 14

DRUG

tofacitinib

60 mg tablet once a day (QD) for 14 days

DRUG

tofacitinib

50 mg tablets two times a day (BID) for 13 days and once on day 14

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-11-30
Primary Completion
2004-04-30
Completion
2004-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01736696 on ClinicalTrials.gov